Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is making significant strides in its proposed merger with Scipher Medicine Corporation. The company has announced that the SEC has declared effective its Form S-4 registration statement, a crucial step towards finalizing the merger. A special meeting for Chemomab shareholders is scheduled for December 4, 2026, to vote on the merger, which is expected to close in the first quarter of 2027, pending approval.
This merger is particularly important as it aims to create a precision medicine powerhouse in immunology. Chemomab, a clinical-stage biotechnology firm, is focused on developing innovative therapeutics for immune-fibrotic diseases, which are often underserved in the pharmaceutical market.
Background
Chemomab Therapeutics Ltd. operates under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is listed on the Nasdaq under the ticker CMMB. Its recent filings include a 6-K form submitted on November 19, 2026, detailing its financial results and corporate updates. The firm has undergone several name changes, previously known as Anchiano Therapeutics Ltd. and BioCancell Ltd.
What the Filing Says
The recent filing includes a press release stating, "Chemomab Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update." It highlights the progress made towards the merger with Scipher, noting that the SEC's declaration of effectiveness of the Form S-4 registration statement is a significant milestone.
Impact
The proposed merger will directly affect Chemomab's shareholders, who will have the opportunity to vote on the merger at the upcoming special meeting. If approved, the merger will create a larger entity that combines Chemomab's clinical-stage anti-CCL24 antibody nebokitug with Scipher's precision medicine capabilities. This merger is anticipated to enhance the combined company's ability to address the substantial market for rheumatoid arthritis treatments, estimated at around $24 billion annually.
What's Next
The next step involves the special shareholder meeting on December 4, 2026, where Chemomab's shareholders will vote on the proposed merger with Scipher. If approved, the merger is expected to close in early 2027, contingent upon satisfying customary closing conditions.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





